Join Our Growing Team

Job Openings

If you’re looking for a career in a growing, innovative company, join Acarix.

At Acarix, there are always opportunities to break new ground and drive change. We empower you to fulfil your ambitions, and we encourage innovation and new thinking as we grow the company. We trust you with responsibility early on, and we expect compliant and ethical behavior and working practices. We look forward to supporting you in your personal development and to be responsive to your aspirations and priorities in life.

No employee or applicant for employment will be discriminated against based on race, color, religion, age, sex, sexual orientation, national origin, ancestry, disability, military or veteran status, genetic information, gender identity, transgender status, marital status or any other classification.

Please submit your resume to [email protected]

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care.

The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures.2

The CADScor System has been used on more than 40,000 patients.3 Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care.1

Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, [email protected]) is the Certified Advisor of Acarix.

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.
  3. Based on commercial patch use since 2017